跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT04890873
NCT04890873已完成1 期

ERX1000 - A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

ERX Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2019年10月17日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
48
试验地点
1
主要终点
Part A (Single Dose Group A9): Incidence and severity of adverse events (AEs)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The primary objective is to assess the safety and tolerability of single and multiple oral doses of ERX1000 in obese subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 55 Years（Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions.
  • •Adult females and males, of any race, between 18 and 55 years of age, inclusive, at Screening.
  • •Females of non-childbearing potential, which is defined as permanently sterile (ie, due to hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), or with bilateral tubal ligation or Essure® (hysteroscopic bilateral tubal occlusion) with confirmation of occlusion of the fallopian tubes performed at least 3 months prior to Screening, or postmenopausal (defined as at least 12 months post cessation of menses without an alternative medical cause and follicle-stimulating hormone [FSH] level
  • •≥ 40 mIU/mL). Males will agree to use contraception and refrain from sperm donation.
  • •Body mass index between 30.0 and 39.9 kg/m^2, inclusive, at Screening.
  • •Glycosylated hemoglobin (HbA1c) level of < 6.5% at Screening (test may be repeated once for confirmation of out-of-range values).
  • •Vital signs at Screening and Check-in as per the following ranges and stable (measured in a supine position after a minimum of 5 minutes of rest):
  • •Systolic blood pressure ≥ 90 and ≤ 140 mmHg
  • •Diastolic blood pressure ≥ 50 and ≤ 90 mmHg
  • •Pulse rate ≥ 50 and ≤ 100 bpm.
  • •In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory evaluations at Screening and/or Check-in as assessed by the Investigator (or designee).

排除标准

  • •Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks prior to dose administration on Day
  • •Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).
  • •Obesity induced by known endocrine or genetic disorders (eg, Cushing syndrome, hypothyroidism, Prader Willi syndrome).
  • •Any previous surgical treatment or procedures with medical devices (such as insertion of lap band or gastric balloons) for obesity (excluding liposuction if performed > 1 year prior to Check-in).
  • •History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, which would increase the subject's risk of participation.
  • •History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair > 6 months prior to Screening will be allowed).
  • •History or evidence of underlying liver disease, including viral (hepatitis B and C) or alcoholic hepatitis, or confirmed diagnosis of nonalcoholic steatohepatitis (NASH); nonalcoholic fatty liver disease with qualifying liver function tests (LFTs) will be allowed.
  • •Gilbert's Syndrome (congenital non-hemolytic hyperbilirubinemia) or suspicion of Gilbert's Syndrome based on total and direct bilirubin.
  • •Laboratory results that exceed the following thresholds at Screening AND Check-in (laboratory tests may be repeated once for confirmation of out-of-range values) as specified:
  • •alanine aminotransferase (ALT) > 1.5 × upper limit of normal (ULN)
  • •aspartate aminotransferase (AST) > 1.5 × ULN
  • •gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), total bilirubin, or International Normalized Ratio (INR) > ULN
  • •Hemoglobinopathy, hemolytic anemia, or chronic anemia (hemoglobin concentration < 13.0 g/dL [130 g/L] for males, < 11.0 g/dL [110 g/L] for females) at Screening or any other condition known to interfere with interpretation of HbA1c measurement
  • •Neutrophils < 1.5 × 109/L deemed clinically significant by Investigator upon a confirmatory repeat
  • •Thyroid-stimulating hormone (TSH) level above the normal range, confirmed on repeat.
  • •History or presence of cardiac arrhythmia (at the discretion of the Investigator) or congenital long QT syndrome.
  • •A QT interval corrected for heart rate using Fridericia's method (QTcF) > 450 msec for males or > 470 msec for females on Screening ECG. At the discretion of the Investigator, ECG may be repeated twice and an average taken of the 3 readings.
  • •The subject has creatinine clearance ≤ 80 mL/minute as calculated using the Cockroft-Gault equation. At the discretion of the Investigator, evaluation may be repeated once to confirm.
  • •History of alcoholism or drug/chemical abuse within 2 years prior to Check in.
  • •Alcohol consumption of > 14 units per week. One unit of alcohol equals 12 oz (360 mL) of beer, 1½ oz (45 mL) of liquor, or 5 oz (150 mL) of wine.
  • •Positive urine drug screen at Screening; or positive alcohol breath test result or positive urine drug screen at Check-in.
  • •Positive hepatitis B surface antigen and/or hepatitis C antibody and/or positive human immunodeficiency virus 1/2 (Appendix 2).
  • •Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days or 5 half-lives prior to dosing, whichever is longer.
  • •Subjects who are actively dieting, have gained or lost > 5 pounds, or using or intend to use any prescription or nonprescription drugs for weight loss including herbal or other dietary supplements within 3 months prior to Check-in.
  • •Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to Check-in and throughout the outpatient Follow-up period.
  • •Use or intend to use any prescription medications/products within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  • •Use or intend to use slow-release medications/products considered to still be active within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  • •Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 14 days prior to Check-in and throughout the outpatient Follow-up period, unless deemed acceptable by the Investigator (or designee).
  • •Consumption of alcohol from 72 hours prior to Check-in.
  • •Use of tobacco- or nicotine-containing products (including nicotine and non-nicotine e-cigarettes, vaping, etc.) within 3 months prior to Check-in, or positive cotinine at Screening or Check-in.
  • •Receipt of blood products within 2 months prior to Check-in.
  • •Donation of blood from 8 weeks prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening.
  • •Poor peripheral venous access.
  • •Have previously completed or withdrawn from this study or any other study investigating ERX1000, and have previously received the investigational product.
  • •Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.

研究组 & 干预措施

ERX1000

Experimental

ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension

Proposed dose level for Part A: 4 mg and 8 mg

Proposed dose level for Part B: 4 and 8 mg. The dose administered will not exceed the highest dose administered in Part A.

干预措施: ERX1000 (Drug)

Placebo

Placebo Comparator

Reference product: Magnesium hydroxide carbonate powder prepared in an oral suspension

干预措施: Placebo (Drug)

结局指标

主要结局

Part A (Single Dose Group A9): Incidence and severity of adverse events (AEs)

时间窗: Day 1 up to end of study (Day 10)

Part A (Single Dose Group A9): Incidence of clinical laboratory abnormalities

时间窗: Screening (Day -28) up to end of study (Day 10)

Part A (Single Dose Group A9): Incidence of 12-lead electrocardiogram (ECG) abnormalities

时间窗: Screening (Day -28 to Day -2), Days 1, 3 and 10

Part A (Single Dose Group A9): Incidence of vital sign abnormalities

时间窗: Screening (Day -28 to Day -2), Check-in (Day -1), Days 1, 3, 4, 5, 6 and 10

Part A (Single Dose Group A9): Incidence of physical examination abnormalities

时间窗: Check-in (Day -1), Days 6 and 10

Part B (Multiple Dose Group B5): Incidence of 12-lead electrocardiogram (ECG) abnormalities

时间窗: Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 4, 7, 10, 19, 25, 28, 30 and 37

Part B (Multiple Dose Group B5): Incidence of vital sign abnormalities

时间窗: Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 19, 22, 25, 28, 30 and 37

Part B (Multiple Dose Group B5): Incidence of physical examination abnormalities

时间窗: Check-in (Day -2), Days 30, 33 and 37

Part B (Multiple Dose Group B6): Incidence of 12-lead electrocardiogram (ECG) abnormalities

时间窗: Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 3, 8, 10, 15, 17, 22, 25, 29, 34 and End of Study (Day 41)

Part B (Multiple Dose Group B6): Incidence of vital sign abnormalities

时间窗: Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 25, 27, 29, 34, 38 and End of Study (Day 41)

Part B (Multiple Dose Group B6): Incidence of physical examination abnormalities

时间窗: Check-in (Day -2), Days 34, 38 and End of Study (Day 41)

Part B (Multiple Dose Group B5 and Multiple Dose Group B6): Incidence and severity of adverse events (AEs)

时间窗: Day 1 up to end of study (For Group B5, Day 37 and for Group B6, Day 41)

Part B (Multiple Dose Group B5 and Multiple Dose Group B6): Incidence of clinical laboratory abnormalities

时间窗: Screening (Day -28), Check-in (Day-2), Days 7, 14, 21, 28, 34 and End of Study (Day 41)

次要结局

  • Part A (Single Dose Group A9): Plasma pharmacokinetic (PK) outcome endpoint of ERX1000, AUC0-t(Day 1, 8 and 10)
  • Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, AUC0-∞(Day 1, 8 and 10)
  • Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, AUC0-τ(Day 1, 8 and 10)
  • Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, Cmax(Day 1, 8 and 10)
  • Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, Ctrough(Day 1, 8 and 10)
  • Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, Tmax(Day 1, 8 and 10)
  • Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, time of last measurable concentration (tlast)(Day 1, 8 and 10)
  • Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, t1/2(Day 1, 8 and 10)
  • Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, apparent total plasma clearance (CL/F)(Day 1, 8 and 10)
  • Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, apparent volume of distribution (Vz/F)(Day 1, 8 and 10)
  • Part A (Single Dose Group A9): Plasma PK outcome endpoint of ERX1000, accumulation ratio (AR).(Day 1, 8 and 10)
  • Part A (Single Dose Group A9): Urine PK outcome endpoint of ERX1000, amount of drug excreted in urine over the sampling period (Aeu)(Day 1)
  • Part A (Single Dose Group A9): Urine PK outcome endpoint of ERX1000, percentage of dose excreted in urine over the sampling interval (%Feu)(Day 1)
  • Part A (Single Dose Group A9): Urine PK outcome endpoint of ERX1000, renal clearance (CLR)(Day 1)
  • Part B (Multiple Dose Group B5): Plasma pharmacokinetic (PK) outcome endpoint of ERX1000, AUC0-t(Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37)
  • Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, AUC0-∞(Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37)
  • Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, AUC0-τ(Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37)
  • Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, Cmax(Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37)
  • Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, Ctrough(Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37)
  • Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, Tmax(Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37)
  • Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, time of last measurable concentration (tlast)(Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37)
  • Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, t1/2(Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37)
  • Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, apparent total plasma clearance (CL/F)(Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37)
  • Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, apparent volume of distribution (Vz/F)(Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37)
  • Part B (Multiple Dose Group B5): Plasma PK outcome endpoint of ERX1000, accumulation ratio (AR).(Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37)
  • Part B (Multiple Dose Group B5): Urine PK outcome endpoint of ERX1000, amount of drug excreted in urine over the sampling period (Aeu)(Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37)
  • Part B (Multiple Dose Group B5): Urine PK outcome endpoint of ERX1000, percentage of dose excreted in urine over the sampling interval (%Feu)(Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37)
  • Part B (Multiple Dose Group B5): Urine PK outcome endpoint of ERX1000, renal clearance (CLR)(Days 1, 7, 10, 13, 19, 22, 25, 28, 31, 33 and 37)
  • Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum lipid -Total cholesterol(Days -1, 14 and 27)
  • Part B (Multiple Dose Group B6): Plasma pharmacokinetic (PK) outcome endpoint of ERX1000, AUC0-t(Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41))
  • Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, AUC0-∞(Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41))
  • Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, AUC0-τ(Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41))
  • Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, Cmax(Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41))
  • Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, Ctrough(Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41))
  • Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, Tmax(Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41))
  • Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, time of last measurable concentration (tlast)(Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41))
  • Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, t1/2(Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41))
  • Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, apparent total plasma clearance (CL/F)(Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41))
  • Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, apparent volume of distribution (Vz/F)(Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41))
  • Part B (Multiple Dose Group B6): Plasma PK outcome endpoint of ERX1000, accumulation ratio (AR).(Days 1, 8, 15, 22, 29, 36, 38 and End of Study (Day 41))
  • Part B (Multiple Dose Group B6): Urine PK outcome endpoint of ERX1000, amount of drug excreted in urine over the sampling period (Aeu)(Day 1 and Day 29)
  • Part B (Multiple Dose Group B6): Urine PK outcome endpoint of ERX1000, percentage of dose excreted in urine over the sampling interval (%Feu)(Day 1 and Day 29)
  • Part B (Multiple Dose Group B6): Urine PK outcome endpoint of ERX1000, renal clearance (CLR)(Day 1 and Day 29)
  • Part B (Multiple Dose Group B5): Pharmacodynamic (PD) outcome endpoint of ERX1000, body weight(Screening (Day -28 to Day -3), Days -1, 8, 15, 22, 28, 30, 33 and 37)
  • Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum leptin(Days -1, 7, 14, 21, 27 and 30)
  • Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum lipid - High-density lipoprotein cholesterol (HDL)(Days -1, 14 and 27)
  • Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum lipid - Low-density lipoprotein cholesterol (LDL)(Days -1, 14 and 27)
  • Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum lipid - Triglyceride(Days -1, 14 and 27)
  • Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, serum insulin(Days 7 and 21)
  • Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - serum glucose(Days -1, 14 and 27)
  • Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - serum insulin(Days -1, 14 and 27)
  • Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, derived from oral glucose tolerance test (OGTT) - Homeostatic Model Assessment of Insulin Resistance(Days -1, 14 and 27)
  • Part B (Multiple Dose Group B5): PD outcome endpoint of ERX1000, assessments derived from oral glucose tolerance test (OGTT) - Matsuda Index(Days -1, 14 and 27)
  • Part B (Multiple Dose Group B6):Pharmacodynamic (PD) outcome endpoint of ERX1000, body weight(Screening (Day -28 to -3), Days -1, 1, 8, 15, 22, 29, 34, 36, 38 and End of Study (Day 41))
  • Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, serum leptin(Day -1 and Day 31)
  • Part B (Multiple Dose Group B6): PD outcome endpoint of ERX1000, serum lipid - High-density lipoprotein cholesterol (HDL)(Day -1 and Day 31)
  • Part B (Multiple Dose Group B6): PD outcome endpoint of ERX1000, serum lipid - Low-density lipoprotein cholesterol (LDL)(Day -1 and Day 31)
  • Part B (Multiple Dose Group B6): PD outcome endpoint of ERX1000, serum lipid -Total cholesterol(Day -1 and Day 31)
  • Part B (Multiple Dose Group B6): PD outcome endpoint of ERX1000, serum lipid - Triglyceride(Day -1 and Day 31)
  • Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, serum insulin(Day -1 and Day 31)
  • Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - serum glucose(Day -1 and Day 31)
  • Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - serum insulin(Day -1 and Day 31)
  • Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, assessment derived from oral glucose tolerance test (OGTT) - Homeostatic Model Assessment of Insulin Resistance(Day -1 and Day 31)
  • Part B (Multiple Dose Group B6):PD outcome endpoint of ERX1000, assessments derived from oral glucose tolerance test (OGTT) - Matsuda Index(Day -1 and Day 31)

研究者

发起方
ERX Pharmaceuticals
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
1 期
DP13 SAD & MAD in Healthy Male SubjectsSafety and Tolerability
NCT03046589Damian Pharma AG48
已完成
1 期
A Study of Nipocalimab in Healthy Male and Female ParticipantsHealthy
NCT04848558Janssen Research & Development, LLC89
终止
1 期
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese ParticipantsSafetyTolerabilityPharmacokineticsPharmacodynamics
NCT02209506Takeda23
已完成
1 期
Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691Hepatitis C Virus
NCT00810758Pfizer24
已完成
1 期
PAC-14028 in Healthy Male VolunteersHealthy
NCT01264224Amorepacific Corporation60